Prostate Cancer | Specialty

Dr. Dreicer on Combination Trials With Radium-223 in mCRPC

November 12th 2016

Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses the potential of combination regimens involving radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Spratt on Growing Role for Genetic Testing in Prostate Cancer

November 9th 2016

Daniel Eidelberg Spratt, MD, assistant professor, radiation oncology, University of Michigan Health System, discusses genetic testing in prostate cancer.

LUGPA Will Create Bundled Payment Models for Prostate Care

November 8th 2016

The Large Urology Group Practice Association has announced the plan to create two alternative payment models that involve bundled payments.

Expert Emphasizes Impact of Robotic Surgery in Field of Prostate Cancer

November 8th 2016

David Albala, MD, discusses some of the benefits of robotic surgery and the impact it has had on the field of prostate cancer, as well as methods that larger urology groups can use to better achieve compliance.

Dr. Concepcion on the Use of Eligard in Prostate Cancer Treatment

November 7th 2016

Raoul Concepcion, MD, director, Comprehensive Prostate Center, discusses the use of Eligard in the treatment of prostate cancer with OncLive during the LUGPA Annual Meeting.

Dr. Buffington on The Use of Fusion MRI in Prostate Cancer

November 7th 2016

Philip J. Buffington, MD, Chief Medical Officer, The Urology Group, discussed the use of fusion MRI in prostate cancer with OncLive during the LUGPA Annual Meeting.

Dr. Rahul Tendulkar on Managing Side Effects of Radical Prostatectomy

November 7th 2016

Rahul Tendulkar, MD, associate staff, radiation oncology, Cleveland Clinic, discusses the side effects of a radical prostatectomy for men with prostate cancer.

Dr. David Albala on The Role of Robotic Surgery in Prostate Cancer

November 6th 2016

Urology Expert Speaks on Key Advancements, PSA Testing in Prostate Cancer

November 5th 2016

The life expectancy of patients with metastatic castrate-resistant prostate cancer has doubled in recent years thanks to a multitude of new therapies, and there are still many more advancements to come.

Dr. Richard Harris on Advancements on the Horizon in Prostate Cancer

November 4th 2016

Richard Harris, MD, of UroPartners, says there are many exciting advancements currently happening in the field of prostate cancer. Harris shared his insights during an interview with OncLive at the 2016 LUGPA Annual Meeting.

Dr. Gary Kirsh on This Exciting Phase in Prostate Cancer Care

November 4th 2016

Gary Kirsh, MD, President of The Urology Group and the Large Urology Group Practice Association (LUGPA), discusses this exciting phase in prostate cancer care. Kirsh shared his insights during an interview with OncLive at the 2016 LUGPA Annual Meeting.

Dr. Yuh on Outcomes Between RT and Surgery in Prostate Cancer

November 4th 2016

Bertram Yuh, MD, an assistant clinical professor of Urologic Oncology and a urologic oncology surgeon at City of Hope, compares the outcomes with surgery and radiation treatment in patients with localized prostate cancer. Yuh shared this insight in an interview during the 2016 OncLive State of the Science Summit on GU Cancer.

Dr. Lau on Controversies Surrounding Prostate Cancer Screening

November 1st 2016

Clayton S. Lau, MD, director, Urologic Oncology, director, Robotic Surgery, Prostate Cancer Surgery, interim chair of Urology, City of Hope, discusses the controversies surrounding prostate cancer screening. Lau spoke on this in an interview during the 2016 OncLive State of the Science Summit on GU Cancer.

Differentiating Among Surgery, RT, and Active Surveillance in Localized Prostate Cancer

November 1st 2016

Surgery and radiation therapy are standard treatment options for localized prostate cancer, but are not comparative to one another.

Dr. Zagaja on Major Benefit With Prostatectomy

November 1st 2016

Gregory Zagaja, MD, professor of Surgery, director of the Prostate Cancer Center at the University of Chicago Medicine, discusses the benefits of radical prostatectomy for patients with prostate cancer. Zagaja shared this insight during an interview at the 2016 OncLive State of the Science Summit on GU and Prostate Cancer.

Dr. Den on Radiation Therapy in Prostate Cancer

October 31st 2016

Robert B. Den, MD, associate professor of Radiation Oncology, Jefferson Health, discusses the use of radiation therapy as a treatment for patients with prostate cancer.

Dr. Eggener on PSA-Based Screening in Early-Stage Prostate Cancer

October 31st 2016

Scott Eggener, MD, associate professor of Surgery, Urologic Oncology, at the University of Chicago Medicine, discusses his views on PSA-based screening and how to appropriately use it for patients with early-stage prostate cancer. Eggier shared these thoughts during the 2016 OncLive State of the Science Summit on GU and Prostate Cancer.

Active Surveillance a Valued Approach for Early Prostate Cancer

October 28th 2016

Before undergoing surgery, radiation therapy, or a systemic treatment, Clayton S. Lau, MD, advises that the active surveillance approach for some patients with early prostate cancer is likely a more effective approach—but they should be better educated on it.

Dr. Yamoah on Racial Disparities in Prostate Cancer

October 27th 2016

Kosj Yamoah, MD, a radiation oncologist at Moffit Cancer Center, discusses reasons for understanding the racial disparities in patients with prostate cancer. Yamoah shared this insight during an interview at the 2016 OncLive State of the Science Summit on Genitourinary Cancers.

Dr. Neeraj Agarwal on PROSTVAC and Other Immunotherapies in Prostate Cancer

October 27th 2016

Neeraj Agarwal, MD associate professor in the Division of Oncology, Department of Medicine, director of the Genitourinary Medical Oncology Program, Huntsman Cancer Institute at the University of Utah, discusses the pox viral vaccine rilimogene galvacirepvec/rilimogene glafolivec (PROSTVAC) and the future of immunotherapy in prostate cancer.